Welcome to Altum sequencing
We now are service provider in quantitative PCR, Next Generation Sequencing and bioinformatic analysis
Altum has expanded its services portfolio to molecular diagnosis clinical test and cancer biology research, including tumor profiling in liquid biopsy and, as naturally, minimal residual disease assesment .
We now are service provider in quantitative PCR, Next Generation Sequencing and bioinformatic analysis with a turnaround time compatible with the clinical workout.
Full-service genetic lab for clinical research
Altum Sequencing offers its services to the pharma industry to develop genetic characterization of patients enrolled in clinical trials, from baseline genetic screening to NGS based MRD testing and definition of resistance related alterations.
Our services include analysis of diagnosis / baseline samples to identify genetic alterations related with progression, drug response and clinical outcome. From these genetic alterations we select the best markers to be tracked in follow-up samples (MRD).
We have validated our proprietary MRD analysis in several proliferative diseases including: